MCID: TXP001
MIFTS: 60

Toxoplasmosis

Categories: Blood diseases, Fetal diseases, Immune diseases, Infectious diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Toxoplasmosis

MalaCards integrated aliases for Toxoplasmosis:

Name: Toxoplasmosis 12 74 54 42 3 43 15 17 71 32
Multisystemic Disseminated Toxoplasmosis 71
Disseminated Toxoplasmosis 12

Classifications:



External Ids:

Disease Ontology 12 DOID:9965
ICD9CM 34 130
MeSH 43 D014123
NCIt 49 C3418
SNOMED-CT 67 187192000
ICD10 32 B58 B58.8 B58.9
UMLS 71 C0040558 C0343816

Summaries for Toxoplasmosis

MedlinePlus : 42 Toxoplasmosis is a disease caused by the parasite Toxoplasma gondii. More than 60 million people in the U.S. have the parasite. Most of them don't get sick. But the parasite causes serious problems for some people. These include people with weak immune systems and babies whose mothers become infected for the first time during pregnancy. Problems can include damage to the brain, eyes, and other organs. You can get toxoplasmosis from Waste from an infected cat Eating contaminated meat that is raw or not well cooked Using utensils or cutting boards after they've had contact with contaminated raw meat Drinking infected water Receiving an infected organ transplant or blood transfusion Most people with toxoplasmosis don't need treatment. There are drugs to treat it for pregnant women and people with weak immune systems. Centers for Disease Control and Prevention

MalaCards based summary : Toxoplasmosis, also known as multisystemic disseminated toxoplasmosis, is related to ocular toxoplasmosis and congenital toxoplasmosis, and has symptoms including fever and pruritus. An important gene associated with Toxoplasmosis is CD40LG (CD40 Ligand), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Sulfamethoxazole and Trimethoprim have been mentioned in the context of this disorder. Affiliated tissues include testes, brain and lymph node, and related phenotypes are Increased viability with MLN4924 (a NAE inhibitor) and Increased viability with MLN4924 (a NAE inhibitor)

Disease Ontology : 12 A coccidiosis that has material basis in protozoan Toxoplasma gondii. The parasite effects most genera of warm-blooded animals, including humans, but the primary host is the felid (cat) family. Animals are infected by eating infected meat, by ingestion of feces of a cat that has itself recently been infected, or transmission by mother to fetus. The symptoms include bilateral, nontender cervical or axillary lymphadenopathy, fever, malaise, myalgia, hepatosplenomegaly, anemia and leukopenia.

CDC : 3 Toxoplasmosis is considered to be a leading cause of death attributed to foodborne illness in the United States. More than 40 million men, women, and children in the U.S. carry the Toxoplasma parasite, but very few have symptoms because the immune system usually keeps the parasite from causing illness.However, women newly infected with Toxoplasma during or shortly before pregnancy and anyone with a compromised immune system should be aware that toxoplasmosis can have severe consequences. Toxoplasmosis is considered one of the neglected parasitic infections of the United States, a group of five parasitic diseases that have been targeted by CDC for public health action.

Wikipedia : 74 Toxoplasmosis is a parasitic disease caused by Toxoplasma gondii. Infections with toxoplasmosis usually... more...

Related Diseases for Toxoplasmosis

Diseases in the Toxoplasmosis family:

Congenital Toxoplasmosis

Diseases related to Toxoplasmosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1130)
# Related Disease Score Top Affiliating Genes
1 ocular toxoplasmosis 35.0 CD79A CD40LG CCR5
2 congenital toxoplasmosis 34.5 NLRP1 IL10 HLA-DQB1 HLA-DQA1 DHFR CD79A
3 chorioretinitis 31.6 TNF IL6 IL10 IFNG DHFR CD40LG
4 human immunodeficiency virus type 1 31.4 TNF STAT1 IL10 IFNG CD40 CCR5
5 posterior uveitis 31.4 TNF IL6 IL4 IFNG
6 hydrocephalus 31.4 TNF TLR4 TLR2 TGFB1 IL10 IFNG
7 lymphadenitis 31.3 TNF TLR4 IL1B IL10 IFNG
8 uveitis 31.3 TNF IL6 IL4 IL1B IL10 IFNG
9 choroiditis 31.3 TNF IL10 IFNG CD40LG
10 iridocyclitis 31.2 TNF IL6 IL10 CD40LG
11 toxocariasis 31.2 IL4 IL10 CD40LG
12 acquired immunodeficiency syndrome 31.1 TNF IL6 IL1B IL10 IFNG CD79A
13 allergic hypersensitivity disease 31.0 TNF IL4 IL10 IFNG
14 retinal detachment 31.0 TNF TGFB1 IL6 IL10 IFNG
15 cytomegalovirus infection 31.0 TNF IL6 IL1B
16 histoplasmosis 30.9 TNF STAT1 IFNG HLA-DQA1 CD40LG
17 myositis 30.9 TNF IL6 IL1B IFNG HLA-DQA1
18 vasculitis 30.9 TNF IL6 IL10 CD79A CD40LG
19 trichinosis 30.9 IL4 IL10 CD40LG
20 cryptococcosis 30.9 TNF IL4 IL10 IFNG
21 exanthem 30.9 TNF IL6 IL1B IL10 IFNG CD40LG
22 central nervous system lymphoma 30.9 TNF MYD88 IL6 IL10
23 progressive multifocal leukoencephalopathy 30.9 TNF STAT1 CD40LG
24 scleritis 30.9 TNF IL4 IFNG
25 encephalitis 30.9 TNF TLR2 STAT1 IL6 IL4 IL1B
26 syphilis 30.9 TNF IL6 IFNG CD79A CD40LG CCR5
27 pneumocystosis 30.8 TNF IL6 DHFR CD40LG CCR5
28 schistosomiasis 30.8 TNF IL4 IL10 IFNG CD40LG
29 panuveitis 30.8 TNF IL6 IL10 HLA-DQB1 CD40LG
30 myelitis 30.8 TNF IL6 IL10 CD40LG
31 tuberculous meningitis 30.8 TNF TLR2 TGFB1
32 pancytopenia 30.7 IL6 IFNG DHFR CD40LG
33 acute graft versus host disease 30.7 TNF IL4 IL10 IFNG
34 congenital cytomegalovirus 30.7 TNF TLR2 IL1B
35 meningoencephalitis 30.7 TNF IL6 IL4 IL1B IL10 CD79A
36 cryptosporidiosis 30.7 IFNG DHFR CD79A CD40LG
37 lymphopenia 30.7 IL6 IL4 IL10 IFNG
38 pericarditis 30.6 TNF IL6 IL1B IFNG CD40LG
39 lymphoma 30.6 MYD88 IL6 IL4 IL10 CD40LG CD40
40 graft-versus-host disease 30.6 TNF IL6 IL1B IL10 IFNG HLA-DQB1
41 hemolytic anemia 30.6 TNF IL4 IL10 IFNG CD40LG
42 cytomegalovirus retinitis 30.6 TNF IL10 IFNG HLA-DQB1 CD40LG CCR5
43 miliary tuberculosis 30.6 TNF IFNG CD40LG
44 macular retinal edema 30.6 TNF IL6 IL1B
45 central nervous system disease 30.6 TNF IL6 IL1B IFNG CCR5
46 encephalomalacia 30.5 TNF IL6 IL1B
47 eosinophilic meningitis 30.5 IL4 IL10 CD40LG
48 listeriosis 30.5 TNF TLR4 TLR2 MYD88 IL6 IL1B
49 campylobacteriosis 30.5 TLR4 STAT1 IL1B IFNG
50 alopecia 30.5 TNF IL4 IL1B IFNG

Graphical network of the top 20 diseases related to Toxoplasmosis:



Diseases related to Toxoplasmosis

Symptoms & Phenotypes for Toxoplasmosis

UMLS symptoms related to Toxoplasmosis:


fever, pruritus

GenomeRNAi Phenotypes related to Toxoplasmosis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-1 9.73 DHFR HLA-DQB1
2 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-2 9.73 CD40LG DHFR IL10 IL1B MYD88 NLRP1
3 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.73 CD40 DHFR
4 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.55 CD40LG IL10 IL1B MYD88 NLRP1 STAT1
5 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.55 HLA-DQB1 IL10 IL1B MYD88 NLRP1 STAT1
6 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-3 9.55 DHFR

MGI Mouse Phenotypes related to Toxoplasmosis:

45 (show all 20)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.55 ALOX12 CCR5 CD40 CD40LG CD79A DHFR
2 immune system MP:0005387 10.52 ALOX12 CCR5 CD40 CD40LG CD79A DHFR
3 homeostasis/metabolism MP:0005376 10.51 ALOX12 CCR5 CD40 CD40LG CD79A DHFR
4 cellular MP:0005384 10.46 CCR5 CD40LG CD79A DHFR HLA-DQB1 IFNG
5 cardiovascular system MP:0005385 10.44 CCR5 CD40LG DHFR HLA-DQB1 IFNG IL10
6 endocrine/exocrine gland MP:0005379 10.38 CD40 CD40LG HLA-DQA1 HLA-DQB1 IFNG IL10
7 mortality/aging MP:0010768 10.38 CCR5 CD40LG CD79A DHFR HLA-DQB1 IFNG
8 growth/size/body region MP:0005378 10.37 DHFR HLA-DQB1 IFNG IL10 IL1B IL4
9 digestive/alimentary MP:0005381 10.35 CCR5 HLA-DQB1 IFNG IL10 IL4 IL6
10 liver/biliary system MP:0005370 10.34 CCR5 CD79A DHFR HLA-DQB1 IFNG IL10
11 integument MP:0010771 10.32 ALOX12 CD40LG DHFR IFNG IL10 IL1B
12 nervous system MP:0003631 10.31 CCR5 CD40 CD40LG CD79A HLA-DQB1 IFNG
13 neoplasm MP:0002006 10.21 CCR5 CD79A IFNG IL10 IL1B IL6
14 muscle MP:0005369 10.2 CCR5 DHFR HLA-DQB1 IFNG IL10 IL6
15 renal/urinary system MP:0005367 10.06 CD40 CD40LG CD79A HLA-DQB1 IFNG IL4
16 normal MP:0002873 10.02 CD40 CD79A HLA-DQB1 IFNG IL10 IL4
17 reproductive system MP:0005389 10 CCR5 CD40LG HLA-DQB1 IFNG IL10 IL4
18 respiratory system MP:0005388 9.9 HLA-DQB1 IFNG IL10 IL4 IL6 MYD88
19 skeleton MP:0005390 9.77 CD40 CD40LG IFNG IL10 IL1B IL4
20 vision/eye MP:0005391 9.32 CCR5 IFNG IL10 IL4 IL6 MYD88

Drugs & Therapeutics for Toxoplasmosis

Drugs for Toxoplasmosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 104)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sulfamethoxazole Approved Phase 4 723-46-6 5329
2
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
3
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
4
Sulfadiazine Approved, Investigational, Vet_approved Phase 4 68-35-9 5215
5
Levoleucovorin Approved, Investigational Phase 4 68538-85-2
6
Spiramycin Approved Phase 4 24916-50-5
7 Trimethoprim, Sulfamethoxazole Drug Combination Phase 4
8 Anticonvulsants Phase 4
9 Neurotransmitter Agents Phase 4
10 Anti-Bacterial Agents Phase 4
11 Vitamins Phase 4
12 Micronutrients Phase 4
13 Antidotes Phase 4
14 Hormones Phase 4
15 Nutrients Phase 4
16 Trace Elements Phase 4
17 Calcium, Dietary Phase 4
18 Protective Agents Phase 4
19
Calcium Nutraceutical Phase 4 7440-70-2 271
20
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
21
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
22
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
23
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
24
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
25
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
26 Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
27
Letrozole Approved, Investigational Phase 3 112809-51-5 3902
28
Lactitol Approved, Investigational Phase 3 585-88-6, 585-86-4 493591
29
Zidovudine Approved Phase 3 30516-87-1 35370
30
Azithromycin Approved Phase 3 83905-01-5 447043 55185
31
Pentamidine Approved, Investigational Phase 3 100-33-4 4735
32
Dapsone Approved, Investigational Phase 3 80-08-0 2955
33
Clotrimazole Approved, Vet_approved Phase 3 23593-75-1 2812
34
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
35
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
36
Rifabutin Approved, Investigational Phase 3 72559-06-9 6323490 46783538
37
Mefloquine Approved, Investigational Phase 3 53230-10-7 4046
38
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
39 Anti-Inflammatory Agents Phase 3
40 Antineoplastic Agents, Hormonal Phase 3
41 glucocorticoids Phase 3
42 Antiemetics Phase 3
43 Gastrointestinal Agents Phase 3
44 Methylprednisolone Acetate Phase 3
45 Progestins Phase 3
46 Estrogen Antagonists Phase 3
47 Estrogen Receptor Antagonists Phase 3
48 Estrogens Phase 3
49 Aromatase Inhibitors Phase 3
50 Anti-Infective Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 61)
# Name Status NCT ID Phase Drugs
1 Pilot Trial of Valproate as Adjunctive Treatment for Toxoplasma Gondii Completed NCT02011750 Phase 4 Sodium Valproate treatment;Placebo
2 Pyrimethamine Plus Sulfadiazine Versus Trimethoprim Plus Sulfamethoxazole for Treatment of Toxoplasmic Encephalitis in AIDS Patients: A Randomized Controlled Trial. Completed NCT00367081 Phase 4 TMX-SMX (Bactrim(R));Pyrimethamine plus Sulfadiazine plus leucoverin
3 Phase IV Randomized Study of Pyrimethamine, Sulfadiazine, and Leucovorin Calcium for Congenital Toxoplasmosis Recruiting NCT00004317 Phase 4 Leucovorin calcium;Pyrimethamine;Spiramycin;Sulfadiazine
4 To Compare Intravitreal Clindamycin & Dexamethasone With Classic Treatment of Toxoplasmic Retinochoroiditis Unknown status NCT00372294 Phase 3 pyrimethamine-sulfadiazine + prednisolone;Clindamycin+Dexamethasone
5 Multicentre, Randomised Study to Determine the Relative Efficacy of Two Therapeutic Strategies in the Treatment of Children With Congenital Toxoplasmosis Unknown status NCT01202500 Phase 3
6 Effect of Acupuncture Pre-treatment Combined With Letrozole on Live Birth in Infertile Women With Polycystic Ovary Syndrome Unknown status NCT02491320 Phase 3 Letrozole
7 Multicenter, Randomized Clinical Trial to Compare the Efficacy and Tolerance of Prenatal Therapy With Pyrimethamine + Sulfadiazine vs Spiramycine to Reduce Vertical Transmission of Toxoplasma Gondii Following Primary Infection in Pregnancy Completed NCT01189448 Phase 3 Pyrimethamine/Sulfadiazine;Spiramycine
8 Influence of Trimethoprim-sulfamethoxazole for the Recurrence of Retinochoroiditis Toxoplasma Gondii Completed NCT01449877 Phase 3 Trimethoprim-Sulfamethoxazole
9 A Randomized Trial of Three Anti-Pneumocystis Agents Plus Zidovudine for the Primary Prevention of Serious Infections in Patients With Advanced HIV Infection Completed NCT00000991 Phase 3 Pentamidine isethionate;Sulfamethoxazole-Trimethoprim;Dapsone;Zidovudine
10 Effect of Add-on Anti-Toxoplasmosis Treatment on Parameters Defining Toxoplasma Gondii Infection and on Psychopathology in Patients With Schizophrenia or Major Depression Serologically Positive for Toxoplasma Gondii - Phase 3 Study Completed NCT00300404 Phase 3 daraprim;pyrimethamine;folinic acid
11 A Randomized Study of Daily and Intermittent Prophylactic Regimens for the Prevention of Disseminated Mycobacterium Avium Complex (MAC) and Fungal Infections in HIV-Infected Patients Completed NCT00002122 Phase 3 Azithromycin;Rifabutin;Fluconazole
12 Prevention of Pregnancy-associated Malaria in HIV-infected Women : Randomised Controlled Trial Testing Cotrimoxazole Prophylaxis Versus Intermittent Preventive Treatment With Mefloquine Completed NCT00970879 Phase 3 cotrimoxazole;mefloquine
13 Randomized Comparative Study of Fluconazole Versus Clotrimazole Troches in the Prevention of Serious Fungal Infection in Patients With AIDS or Advanced AIDS-Related Complex. (A Nested Study of ACTG 081) Completed NCT00000676 Phase 3 Clotrimazole;Fluconazole
14 Primary Prophylaxis of Cerebral Toxoplasmosis in HIV-Infected Patients Completed NCT00000643 Phase 2 Pyrimethamine;Leucovorin calcium
15 Phase II Randomized Open-Label Trial of Atovaquone Plus Pyrimethamine and Atovaquone Plus Sulfadiazine for the Treatment of Acute Toxoplasmic Encephalitis Completed NCT00000794 Phase 2 Sulfadiazine;Clarithromycin;Atovaquone;Pyrimethamine;Leucovorin calcium
16 A Double-Blind Trial of Adjunctive Valacyclovir to Improve Cognition in Early Phase Schizophrenia Completed NCT02008773 Phase 2 Valacyclovir HCI 500 mg tablets;placebo
17 Phase I/II Study of SOD1 Inhibition by Pyrimethamine in Familial ALS Completed NCT01083667 Phase 1, Phase 2 Pyrimethamine
18 Adjunctive Dexamethasone for Cerebral Toxoplasmosis: a Double-blinded Randomized Controlled Trial Not yet recruiting NCT04341155 Phase 2 Dexamethasone;Placebo
19 Treatment of the Bilateral Severe Uveitis by IVT of Regulator T-cells: Study of Tolerance of Dose Suspended NCT02494492 Phase 1, Phase 2
20 Antibodies Screening in Multiple Sclerosis as a Part of an International Survey in Autoimmune Diseases. Unknown status NCT00230204 Phase 1
21 Pyrimethamine Pharmacokinetics in HIV Positive Patients Seropositive for Toxoplasma Gondii Completed NCT00000973 Phase 1 Pyrimethamine;Leucovorin calcium;Zidovudine
22 A Dose-Escalation, Phase I/II Study of Oral Azithromycin and Pyrimethamine for the Treatment of Toxoplasmic Encephalitis in Patients With AIDS Completed NCT00000966 Phase 1 Azithromycin;Pyrimethamine;Leucovorin calcium
23 A Single Centre, Open-label, Parallel-group, Single Oral Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Pyrimethamine in Healthy Japanese and Caucasian Male Subjects Completed NCT03258762 Phase 1 Pyrimethamine;Calcium folinate
24 The Influence of Atazanavir-ritonavir and Efavirenz on Atovaquone Pharmacokinetics in HIV-infected Volunteers Completed NCT01479361 Phase 1 Atovaquone 750 mg twice daily;Atovaquone 1500 mg twice daily
25 A Phase I Study of Autologous, Activated CD8(+) Lymphocytes Expanded In Vitro and Infused With or Without Recombinant Interleukin-2 to Patients With AIDS or Severe ARC Completed NCT00000680 Phase 1 Zidovudine;Aldesleukin
26 A Dose-Escalated, Double-Blind, Placebo-Controlled, Randomized Phase I Clinical Trial of Pyrimethamine in Patients Affected With Chronic GM2 Gangliosidosis (Tay-Sachs or Sandhoff Variants) Withdrawn NCT00679744 Phase 1 Pyrimethamine
27 A Cross-Sectional Study of HIV-Related Neurological Disorders in Ten Countries of the Asia Pacific Region Unknown status NCT00168246
28 Impact of Particulate Matter on Mothers and Babies in Antwerp (IPANEMA), a Prospective Cohort Study on the Impact of Pollutants and Particulate Matter in Pregnancy: Methodology and Design Unknown status NCT02592005
29 Vertical Exposure to Zika Virus and Its Consequences for Child Neurodevelopment: Cohort Study in Fiocruz/IFF Unknown status NCT03255369
30 An Investigation of Cognitive Functioning and Brain Metabolites in Patients With Non-Cirrhotic Hepatitis-C Both Pre- and Post-Treatment With Antiviral Medication Unknown status NCT00188201
31 Toxoplasmic Encephalitis in Patients With AIDS. Treatment and Prevention of Relapse Completed NCT00002064 Pyrimethamine;Clindamycin
32 A Pilot Study of 566C80 for the Salvage Treatment of Toxoplasmic Encephalitis in Patients Infected With the Human Immunodeficiency Virus (HIV) Who Have Failed or Are Intolerant of Pyrimethamine-Sulfadiazine Completed NCT00001994 Atovaquone
33 Evaluation of Biological Biomarkers Diagnostic of Toxoplasmosis Uveitis Completed NCT02843438 Anti-toxoplasmosis treatment;Anti-inflammatory treatments
34 Spectral Optical Coherence Tomography Findings in Patients With Ocular Toxoplasmosis : a Retrospective Study Completed NCT04219176
35 Cerebral Toxoplasmosis and AIDS in the French Departments of America (DFA). Diagnostic Contribution of a PCR Assay and Genetic Diversity of Toxoplasma Gondii. Completed NCT00803621
36 Comparison of Immunoblotting (IgA and IgG) and the Goldmann-Witmer Coefficient for Diagnosis of Ocular Toxoplasmosis in Immunocompetent Patients Completed NCT03948750
37 A Randomized Prospective Study of Pyrimethamine Therapy for Prevention of Toxoplasmic Encephalitis in HIV-Infected Individuals With Serologic Evidence of Latent Toxoplasma Gondii Infection Completed NCT00000666 Pyrimethamine
38 Diagnostics of Intestinal Parasitosis in Inhabitants of Kuyavian-Pomeranian Province in Poland Completed NCT03490435
39 AIDS Defining Opportunistic Infections in Naive HIV Cases Completed NCT03993093
40 A Pilot Study of Oral Clindamycin and Pyrimethamine for the Treatment of Toxoplasmic Encephalitis in Patients With AIDS Completed NCT00000674 Pyrimethamine;Leucovorin calcium;Clindamycin
41 Intravitreal Bevacizumab in Recalcitrant Inflammatory Ocular Neovascularization: Multicenter Collaborative Study Completed NCT00645697
42 The Evaluation of Focal Contrast-Enhancing Brain Lesions in HIV-Infected Patients Completed NCT00226304
43 Discontinuation of Primary and Secondary Prophylaxis for Opportunistic Infections in HIV-infected Patients Who Had CD4+ Cell Count <200 Cells/mm3 But Undetectable Plasma HIV-1 RNA Completed NCT01392430
44 AIDS-Associated Heart Disease -- Incidence and Etiology Completed NCT00005228
45 Studies of Ocular Complications of AIDS (SOCA) Completed NCT00000168
46 HBIG for Prevention of Mother-to-infant HBV Transmission Completed NCT02312531 Hepatitis B immunoglobulin
47 WEUSKOP5522: Observational Drug Exposure Registry for Long-Term Follow-Up of Subjects Exposed to GSK2248761 Completed NCT01458132
48 Pregnancy Loss Between 15 and 22 Weeks SA Within the Network of Perinatal Period of Western Brittany : Case Control Study Completed NCT03668743
49 Complement Factor H Haplotypes and Smoking in Age-related Macular Degeneration Completed NCT01115231
50 The Impact of Pharmacists' Interventions on the Quality of Life of HIV-TB Co-infection Outpatients in Indonesia: a Therapeutic Drug Monitoring (TDM) Approach Completed NCT04325438

Search NIH Clinical Center for Toxoplasmosis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


CLINDAMYCIN PHOSPHATE PWDR
TRIMETHOPRIM SULFATE

Cochrane evidence based reviews: toxoplasmosis

Genetic Tests for Toxoplasmosis

Anatomical Context for Toxoplasmosis

MalaCards organs/tissues related to Toxoplasmosis:

40
Testes, Brain, Lymph Node, Eye, T Cells, Heart, Bone

Publications for Toxoplasmosis

Articles related to Toxoplasmosis:

(show top 50) (show all 14743)
# Title Authors PMID Year
1
Immunodiagnostics of cerebral toxoplasmosis depending on permeability of blood-brain barrier. 61 42
32248160 2020
2
A study for precision diagnosing and treatment strategies in difficult-to-treat AIDS cases and HIV-infected patients with highly fatal or highly disabling opportunistic infections. 42
32443329 2020
3
Mastering Toxoplasma sex and sleep. 42
32218508 2020
4
High diagnostic efficiency of IgM-ELISA with the use of multiple antigen peptides (MAP1) from T. gondii ESA (SAG-1, GRA-1 and GRA-7), in acute toxoplasmosis. 54 61
20464125 2010
5
Toxoplasmosis in pregnancy: determination of IgM, IgG and avidity in filter paper-embedded blood. 54 61
19554010 2009
6
Recovery of anti-Toxoplasma gondii immunoglobulin M in stored guthrie card blood spots. 54 61
19494076 2009
7
[Seroprevalence of toxoplasmosis in pregnant women in Rabat, Morocco]. 61 54
17982862 2007
8
Reduced risk of toxoplasma encephalitis in HIV-infected patients--a prospective study from Gauteng, South Africa. 61 54
17686219 2007
9
Evaluation of a real-time PCR assay based on the repetitive B1 gene for the detection of Toxoplasma gondii in human peripheral blood. 61 54
17385062 2007
10
Fast dipstick dye immunoassay for detection of immunoglobulin G (IgG) and IgM antibodies of human toxoplasmosis. 61 54
15643007 2005
11
Targeting DHFR in parasitic protozoa. 61 54
15718161 2005
12
Lacrimal secretory IgA in active posterior uveitis induced by Toxoplasma gondii. 61 54
15761603 2004
13
Synthesis, biological activity and molecular modeling of 6-benzylthioinosine analogues as subversive substrates of Toxoplasma gondii adenosine kinase. 54 61
15055998 2004
14
CD154 activates macrophage antimicrobial activity in the absence of IFN-gamma through a TNF-alpha-dependent mechanism. 61 54
14662879 2003
15
Toxoplasmosis in pregnant Sudanese women. 61 54
12939674 2003
16
[Prospective study of pregnants and babies with risk of congenital toxoplasmosis in municipal district of Rio Grande do Sul]. 61 54
12937726 2003
17
The significance of complement fixation test in clinical diagnosis of toxoplasmosis. 54 61
14594352 2003
18
Immunoglobulin M (IgM)-glycoinositolphospholipid enzyme-linked immunosorbent assay: an immunoenzymatic assay for discrimination between patients with acute toxoplasmosis and those with persistent parasite-specific IgM antibodies. 61 54
11923364 2002
19
Disseminated histoplasmosis presenting as pyoderma gangrenosum-like lesions in a patient with acquired immunodeficiency syndrome. 61 54
11703524 2001
20
Seroepidemiological study of Toxoplasma gondii infection in the human population in the Eastern Region. 54 61
11255603 2001
21
Vitritis as the primary manifestation of ocular syphilis in patients with HIV infection. 61 54
9512147 1998
22
IgM and IgA antibody responses in 12 cases of human acquired toxoplasmosis. 54 61
9674283 1997
23
Diagnosis of toxoplasmosis by joint detection of immunoglobulin A and immunoglobulin M. 61 54
9163460 1997
24
Bicentric evaluation of Access Toxo immunoglobulin M (IgM) and IgG assays and IMx toxo IgM and IgG assays and comparison with Platelia Toxo IgM and IgG assays. 54 61
8784554 1996
25
Diagnostic implications of kinetics of immunoglobulin M and A antibody responses to Toxoplasma gondii. 54 61
8735107 1996
26
The cytogenetic effects of pyrimethamine on male mouse germ cells. 61 54
9216789 1996
27
[Diagnosis of acquired toxoplasmosis using simultaneous determination of specific immunoglobulins M, A and E]. 54 61
7489131 1995
28
Evaluation of risk and diagnostic value of quantitative assays for anti-Toxoplasma gondii immunoglobulin A (IgA), IgE, and IgM and analytical study of specific IgG in immunodeficient patients. 54 61
7790453 1995
29
[Comparative study of the serologic response of IgA and IgM type in the diagnosis of acute toxoplasmosis]. 61 54
7865558 1994
30
[Comparison of the diagnostic usefulness of immunoglobulins A and M in acute toxoplasmosis]. 54 61
8159880 1993
31
[Determination of IgG toxoplasma antibodies using ELISA with uniform serum dilutions]. 54 61
8348624 1993
32
Improved serological diagnosis of Toxoplasma gondii infection by detection of immunoglobulin A (IgA) and IgM antibodies against P30 by using the immunoblot technique. 61 54
1624560 1992
33
No interference of rheumatoid factor(s) with toxoplasmosis IgM determination in infancy. 54 61
1728544 1992
34
Pharmacokinetic justification of antiprotozoal therapy. A US perspective. 54 61
1782741 1991
35
Seronegative ocular toxoplasma panuveitis in an immunocompetent patient. 61
32566798 2020
36
Phosphoglycan-sensitized platform for specific detection of anti-glycan IgG and IgM antibodies in serum. 61
32498834 2020
37
2-Amino-1,3,4-thiadiazoles as prospective agents in trypanosomiasis and other parasitoses. 61
32074064 2020
38
Hypothesized behavioral host manipulation by SARS-CoV2/COVID-19 infection. 61
32388138 2020
39
A novel luciferase-linked antibody capture assay (LACA) for the diagnosis of Toxoplasma gondii infection in chickens. 61
32311471 2020
40
Oral sex: A new, and possibly the most dangerous, route of toxoplasmosis transmission. 61
32315924 2020
41
Arctigenin exhibits hepatoprotective activity in Toxoplasma gondii-infected host through HMGB1/TLR4/NF-κB pathway. 61
32361192 2020
42
Temporal expression of Toxoplasma stage-specific genes in brain tissue: coincidence with parasitological and histopathological findings in mice models. 61
32476060 2020
43
Knocking down of the DHFR-TS gene in Toxoplasma gondii using siRNA and assessing the subsequences on toxoplasmosis in mice. 61
32277926 2020
44
Cannabinoid receptors and the proconvulsant effect of toxoplasmosis in mice. 61
32315753 2020
45
Failure to bictegravir and development of resistance mutations in an antiretroviral-experienced patient. 61
31982483 2020
46
Horner Syndrome induced by toxoplasmosis infection in a patient with AIDS and disseminated herpes simplex virus. 61
32346650 2020
47
Visual Outcomes in Presumed Congenital Foveal Toxoplasmosis. 61
32035830 2020
48
Implementation and analysis of Babesia immunoassay testing. 61
32564041 2020
49
Characterization of Congenital Toxoplasmosis in Israel: A 17-year Nationwide Study Experience. 61
32398571 2020
50
General Features and Laboratory Diagnosis of Toxoplasma gondii Infection. 61
32482042 2020

Variations for Toxoplasmosis

Expression for Toxoplasmosis

Search GEO for disease gene expression data for Toxoplasmosis.

Pathways for Toxoplasmosis

Pathways related to Toxoplasmosis according to GeneCards Suite gene sharing:

(show top 50) (show all 100)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.11 TNF TLR4 TLR2 TGFB1 STAT1 NLRP1
2
Show member pathways
13.93 TNF TGFB1 STAT1 IL6 IL4 IL1B
3
Show member pathways
13.82 TNF TLR4 TGFB1 IL6 IL4 IL1B
4
Show member pathways
13.62 TNF TGFB1 STAT1 IL6 IL4 IL1B
5
Show member pathways
13.55 TLR4 TLR2 MYD88 HLA-DQB1 HLA-DQA1 CD79A
6
Show member pathways
13.54 TNF TLR4 TLR2 TGFB1 STAT1 MYD88
7
Show member pathways
13.49 TNF TGFB1 STAT1 MYD88 IL6 IL4
8
Show member pathways
13.45 TNF TGFB1 IL6 IL4 IL1B IL10
9
Show member pathways
13.37 TNF TLR4 TLR2 STAT1 MYD88 IL4
10
Show member pathways
13.22 TNF TLR4 TLR2 TGFB1 STAT1 MYD88
11
Show member pathways
13.11 TNF TLR4 TLR2 STAT1 MYD88 IL6
12
Show member pathways
13.08 TNF TLR4 TLR2 STAT1 IL6 IL4
13
Show member pathways
13 TNF TGFB1 STAT1 IL6 IL4 IL1B
14 12.99 TNF TLR2 STAT1 MYD88 IL6 IL1B
15
Show member pathways
12.99 TNF TLR4 TLR2 STAT1 MYD88 IL6
16
Show member pathways
12.92 TNF TLR4 TLR2 STAT1 NLRP1 MYD88
17
Show member pathways
12.9 TNF TLR4 TLR2 TGFB1 MYD88 IL6
18
Show member pathways
12.85 TNF STAT1 IL1B IFNG CD40LG CD40
19
Show member pathways
12.83 TNF IL4 IL10 IFNG HLA-DQB1 HLA-DQA1
20
Show member pathways
12.78 TNF TLR4 TLR2 MYD88 IL1B CD40LG
21
Show member pathways
12.75 TNF STAT1 IL6 IL1B IL10 IFNG
22 12.69 TNF TLR2 STAT1 NLRP1 MYD88 IL4
23
Show member pathways
12.62 STAT1 IL6 IL4 IL10 IFNG CCR5
24 12.54 TNF TGFB1 IL6 HLA-DQB1 HLA-DQA1 CD40
25
Show member pathways
12.53 TNF TLR2 IL6 IL4 IL1B IFNG
26
Show member pathways
12.53 TNF TLR4 STAT1 MYD88 IL6 IL1B
27
Show member pathways
12.52 TNF IL6 IL4 IL1B IFNG DHFR
28 12.5 TNF TLR4 TLR2 MYD88 IL6 IL1B
29
Show member pathways
12.48 TNF TGFB1 STAT1 IL6 IL4 IL1B
30
Show member pathways
12.47 TNF TLR4 TLR2 TGFB1 STAT1 IL6
31 12.46 TNF TLR4 MYD88 IL1B
32
Show member pathways
12.46 HLA-DQB1 HLA-DQA1 CD40LG CD40
33 12.46 TNF TLR4 STAT1 NLRP1 MYD88 IL6
34 12.43 TNF TLR4 MYD88 IL6 IL1B
35
Show member pathways
12.42 TNF TLR4 TLR2 MYD88 IL6
36
Show member pathways
12.41 TNF IL6 IL10 CCR5
37
Show member pathways
12.41 TNF STAT1 MYD88 IL6 IL1B IL10
38 12.4 TNF TLR4 TLR2 TGFB1 STAT1 IL6
39 12.39 TNF TLR4 TLR2 TGFB1
40
Show member pathways
12.37 TNF TLR4 STAT1 IL1B IFNG
41
Show member pathways
12.37 TNF TLR4 TLR2 STAT1 MYD88 IL6
42
Show member pathways
12.31 TNF TLR4 TLR2 TGFB1 STAT1 MYD88
43 12.29 TNF TLR4 TLR2 TGFB1 STAT1 MYD88
44 12.28 TNF IL6 IL1B IL10
45 12.25 TLR4 TLR2 HLA-DQB1 HLA-DQA1
46 12.24 TNF TLR4 MYD88 IL6 IL1B IL10
47 12.23 HLA-DQB1 HLA-DQA1 CD40LG CD40
48 12.23 TNF TGFB1 STAT1 IL1B IFNG
49 12.23 TNF TLR4 TGFB1 IL6 IL4 IL1B
50 12.22 TNF IL6 IL4 IL10 IFNG CD79A

GO Terms for Toxoplasmosis

Cellular components related to Toxoplasmosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.81 TNF TGFB1 IL6 IL4 IL1B IL10
2 external side of plasma membrane GO:0009897 9.43 TNF TLR4 CD79A CD40LG CD40 CCR5
3 cell surface GO:0009986 9.17 TNF TLR4 TLR2 TGFB1 CD40LG CD40

Biological processes related to Toxoplasmosis according to GeneCards Suite gene sharing:

(show top 50) (show all 110)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.39 TLR4 TLR2 TGFB1 STAT1 MYD88 IL6
2 positive regulation of transcription by RNA polymerase II GO:0045944 10.3 TNF TLR4 TLR2 TGFB1 STAT1 IL6
3 immune system process GO:0002376 10.26 TLR4 TLR2 NLRP1 MYD88 HLA-DQA1 CD79A
4 positive regulation of transcription, DNA-templated GO:0045893 10.24 TNF TGFB1 STAT1 IL6 IL4 IL1B
5 positive regulation of cell proliferation GO:0008284 10.22 TGFB1 STAT1 IL6 IL4 IL1B IFNG
6 negative regulation of apoptotic process GO:0043066 10.21 MYD88 IL6 IL4 IL10 CD40LG ALOX12
7 negative regulation of cell proliferation GO:0008285 10.18 TLR2 TGFB1 IL6 IL1B IL10
8 positive regulation of gene expression GO:0010628 10.13 TNF TLR4 TLR2 TGFB1 MYD88 IL6
9 defense response to bacterium GO:0042742 10.12 TNF TLR4 NLRP1 MYD88 IL10
10 regulation of cell proliferation GO:0042127 10.08 TNF TGFB1 STAT1 MYD88
11 defense response to virus GO:0051607 10.08 STAT1 IL6 IFNG CD40
12 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 10.08 TNF TLR4 MYD88 IL1B CD40
13 positive regulation of protein phosphorylation GO:0001934 10.08 TNF TGFB1 IL1B IFNG CD40
14 response to lipopolysaccharide GO:0032496 10.06 TLR4 TLR2 MYD88 IL1B IL10
15 tumor necrosis factor-mediated signaling pathway GO:0033209 10.03 TNF STAT1 CD40LG CD40
16 positive regulation of DNA-binding transcription factor activity GO:0051091 10.03 TNF IL6 IL1B IL10
17 defense response to Gram-positive bacterium GO:0050830 10.02 TNF TLR2 MYD88 IL6
18 positive regulation of inflammatory response GO:0050729 10.02 TNF TLR4 TLR2 IL1B IFNG
19 cellular response to lipopolysaccharide GO:0071222 10.01 TNF TLR4 MYD88 IL6 IL1B IL10
20 regulation of inflammatory response GO:0050727 10 TNF TLR4 NLRP1 MYD88
21 positive regulation of JNK cascade GO:0046330 10 TNF TLR4 MYD88 IL1B
22 B cell differentiation GO:0030183 10 IL4 IL10 CD79A CD40LG
23 cellular response to mechanical stimulus GO:0071260 9.99 TLR4 TGFB1 MYD88 IL1B CD40
24 interferon-gamma-mediated signaling pathway GO:0060333 9.98 STAT1 IFNG HLA-DQB1 HLA-DQA1
25 cellular response to organic cyclic compound GO:0071407 9.97 TNF TGFB1 STAT1 IL1B
26 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.97 TNF IL6 IL4 IFNG CD40
27 cytokine-mediated signaling pathway GO:0019221 9.97 TNF TGFB1 STAT1 MYD88 IL6 IL4
28 regulation of insulin secretion GO:0050796 9.96 TNF IL1B IFNG
29 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.96 TNF TLR4 TLR2 IL1B
30 positive regulation of T cell proliferation GO:0042102 9.96 IL6 IL4 IL1B CD40LG
31 response to glucocorticoid GO:0051384 9.95 TNF IL6 IL10
32 positive regulation of MAP kinase activity GO:0043406 9.95 TNF TGFB1 CD40
33 humoral immune response GO:0006959 9.95 TNF IL6 IFNG
34 positive regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043280 9.95 TNF NLRP1 ALOX12
35 positive regulation of smooth muscle cell proliferation GO:0048661 9.95 TNF STAT1 MYD88 IL6 ALOX12
36 positive regulation of protein complex assembly GO:0031334 9.94 TNF TGFB1 IFNG
37 positive regulation of tumor necrosis factor production GO:0032760 9.94 TLR4 TLR2 MYD88
38 negative regulation of fat cell differentiation GO:0045599 9.94 TNF TGFB1 IL6
39 positive regulation of blood vessel endothelial cell migration GO:0043536 9.94 TGFB1 CD40 ALOX12
40 positive regulation of nitric oxide biosynthetic process GO:0045429 9.94 TNF TLR4 IL1B IFNG
41 protein kinase B signaling GO:0043491 9.94 TNF TGFB1 IL1B CD40
42 positive regulation of phagocytosis GO:0050766 9.93 TNF IL1B IFNG
43 positive regulation of interferon-gamma production GO:0032729 9.93 TNF TLR4 IL1B
44 extrinsic apoptotic signaling pathway GO:0097191 9.93 TNF TGFB1 IFNG
45 positive regulation of epithelial to mesenchymal transition GO:0010718 9.93 TGFB1 IL6 IL1B
46 B cell proliferation GO:0042100 9.93 IL10 CD79A CD40LG CD40
47 positive regulation of interleukin-6 production GO:0032755 9.93 TNF TLR4 TLR2 MYD88 IL6 IL1B
48 toll-like receptor signaling pathway GO:0002224 9.92 TLR4 TLR2 MYD88
49 positive regulation of pri-miRNA transcription by RNA polymerase II GO:1902895 9.92 TNF TGFB1 IL10
50 positive regulation of B cell proliferation GO:0030890 9.92 TLR4 IL4 CD40

Molecular functions related to Toxoplasmosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.96 TNF TLR4 TLR2 TGFB1 STAT1 NLRP1
2 identical protein binding GO:0042802 9.86 TNF TLR4 TLR2 TGFB1 STAT1 MYD88
3 growth factor activity GO:0008083 9.62 TGFB1 IL6 IL4 IL10
4 MHC class II receptor activity GO:0032395 9.43 HLA-DQB1 HLA-DQA1
5 Toll-like receptor binding GO:0035325 9.4 TLR2 MYD88
6 lipopolysaccharide receptor activity GO:0001875 9.37 TLR4 TLR2
7 tumor necrosis factor receptor binding GO:0005164 9.33 TNF STAT1 CD40LG
8 cytokine activity GO:0005125 9.23 TNF TGFB1 IL6 IL4 IL1B IL10

Sources for Toxoplasmosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....